FAQ: Branded Legacy, Inc. (OTC: BLEG) Acquisition of Bio-Legacy Evaluative Group and Expansion into Intranasal Drug Delivery

What is the main purpose of Branded Legacy’s acquisition of Bio-Legacy Evaluative Group?

The main purpose is to acquire Bio-Legacy’s advanced intranasal drug delivery technologies, including a patented naloxone device, to expand Branded Legacy’s portfolio into high-growth markets for addiction treatments and vaccine accessibility.

Why is the acquisition of Bio-Legacy Evaluative Group significant?

This acquisition is significant because it allows Branded Legacy to enter lucrative markets with Bio-Legacy’s innovative technologies, addressing cost and dosing challenges in a market projected to exceed $1.16 billion by 2032.

How will the acquisition be financed?

The acquisition will be financed through a $1.5 million Preferred D stock transaction, transferring 100% of Bio-Legacy’s equity, assets, and IP to Branded Legacy.

Who will lead Branded Legacy after the acquisition?

Following the closing, Bio-Legacy CEO Amin Janmohamed will assume the roles of CEO and Chairman of Branded Legacy.

When is the manufacturing prototyping and market readiness expected for the naloxone device?

Manufacturing prototyping is targeted for Q3 2025, with market readiness for the naloxone device expected by Q1 2027.

Where can I find more information about Branded Legacy and this acquisition?

For more information, visit Branded Legacy’s website at https://BrandedLegacy.com or view the full press release at https://ibn.fm/5kuAK.

What are the implications of this acquisition for Branded Legacy’s shareholders?

The acquisition is expected to create sustainable value for shareholders by enhancing Branded Legacy’s portfolio with innovative biotech and wellness products, positioning the company in high-growth markets.

What makes Bio-Legacy’s naloxone device unique?

Bio-Legacy’s naloxone device is patented and addresses cost and dosing challenges in the addiction treatment market, making it a unique and valuable addition to Branded Legacy’s portfolio.